Pfizer signs license agreement to allow broader global access to its experimental Covid-19 antiviral pill

Pfizer signs license agreement to allow broader global access to its experimental Covid-19 antiviral pill
KENA BETANCUR/AFP/AFP via Getty Images

Pfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental Covid-19 pill.

The agreement with the Medicines Patent Pool, a United Nations-backed public health organization, would allow generic manufacturers to make the pill widely available in 95 low- and middle-income countries covering 53% of the world’s population, the company said.

The pill, known as PF-07321332 or Paxlovid, is to be given in combination with an older antiviral drug called ritonavir.

Earlier this month Pfizer announced topline results from its trial saying that an interim analysis — done before the trial was scheduled to end — showed an 89% reduction in the risk of hospitalization or death from Covid-19 among people given the drug within the first three days of symptom onset.

“Pfizer will not receive royalties on sales in low-income countries and will further waive royalties on sales in all countries covered by the agreement while COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization,” Pfizer said in the statement.

The-CNN-Wire
™ & © 2021 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.

-advertisement-

Popular Stories

Concert Calendar

Featured Events